Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the optimal duration of anticoagulation therapy (3 months versus 12 months) with direct oral anticoagulant (edoxaban) for isolated distal deep vein thrombosis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Takeshi Morimoto
• Treatments: Anticoagulants; Edoxaban

Criteria

Inclusion Criteria:

• Patients with newly found isolated distal deep vein thrombosis

• Patients complicated with active cancer

• Patients who are scheduled to be treated by anticoagulation therapy.

Exclusion Criteria:

• Patients with anticoagulation therapy for the index event before 10 days of allocation.

• Patient under anticoagulation therapy for the purpose of other than the index event.

• Patients with thrombolysis therapy or IVC filter at the Index event.

• Patients with creatinine clearance less than 30 ml/min.

• Patients who are expected to have a life prognosis of 3 months or less.

• Patients with pulmonary embolism.

• Patients who are not appropriate for the participation of the study.